OLD National Bancorp IN lowered its holdings in Thermo Fisher Scientific Inc (NYSE:TMO) by 6.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 92,039 shares of the medical research company’s stock after selling 6,372 shares during the quarter. Thermo Fisher Scientific accounts for 0.9% of OLD National Bancorp IN’s holdings, making the stock its 29th biggest position. OLD National Bancorp IN’s holdings in Thermo Fisher Scientific were worth $16,058,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the company. Proficio Capital Partners LLC grew its position in Thermo Fisher Scientific by 71.5% during the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares during the period. Sharkey Howes & Javer lifted its holdings in Thermo Fisher Scientific by 1.0% during the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after purchasing an additional 7 shares in the last quarter. FNY Managed Accounts LLC purchased a new position in Thermo Fisher Scientific during the first quarter valued at $153,000. Penserra Capital Management LLC lifted its holdings in Thermo Fisher Scientific by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,150 shares of the medical research company’s stock valued at $176,000 after purchasing an additional 100 shares in the last quarter. Finally, Investment Centers of America Inc. purchased a new position in Thermo Fisher Scientific during the first quarter valued at $200,000. Hedge funds and other institutional investors own 83.52% of the company’s stock.
In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 1,000 shares of the stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $175.20, for a total value of $175,200.00. Following the completion of the sale, the director now directly owns 38,757 shares in the company, valued at $6,790,226.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Peter E. Hornstra sold 3,894 shares of the stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total value of $721,090.92. Following the completion of the sale, the vice president now owns 19,751 shares of the company’s stock, valued at $3,657,490.18. The disclosure for this sale can be found here. Insiders sold 22,738 shares of company stock worth $4,021,512 in the last three months. Insiders own 0.49% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “OLD National Bancorp IN Reduces Position in Thermo Fisher Scientific Inc (NYSE:TMO)” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://ledgergazette.com/2017/09/16/old-national-bancorp-in-cuts-holdings-in-thermo-fisher-scientific-inc-tmo.html.
Several equities analysts have recently weighed in on TMO shares. Cowen and Company reissued an “outperform” rating and issued a $220.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Sunday, September 10th. BidaskClub raised shares of Thermo Fisher Scientific from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Citigroup Inc. reissued a “buy” rating and issued a $201.00 price target (up from $182.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 10th. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Barclays PLC reiterated an “overweight” rating and set a $200.00 price target (up from $190.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 17th. One analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $193.56.
Thermo Fisher Scientific Inc (NYSE TMO) traded down 0.55% on Friday, reaching $190.63. 3,274,947 shares of the company’s stock were exchanged. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $194.30. The firm’s 50 day moving average is $180.21 and its 200 day moving average is $170.53. The stock has a market capitalization of $74.37 billion, a P/E ratio of 33.21 and a beta of 1.05.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. During the same quarter in the prior year, the firm posted $2.03 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. Analysts expect that Thermo Fisher Scientific Inc will post $9.35 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.31%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is 10.45%.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.